C. Morris

633 total citations
19 papers, 494 citations indexed

About

C. Morris is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, C. Morris has authored 19 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in C. Morris's work include Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Melanoma and MAPK Pathways (4 papers). C. Morris is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Melanoma and MAPK Pathways (4 papers). C. Morris collaborates with scholars based in United Kingdom, United States and France. C. Morris's co-authors include Mireille Cantarini, Karin Kemsley, Mark R. Middleton, Lars Bastholt, Caroline Robert, Malcolm Ranson, J. A. Sosman, Reinhard Dummer, Paul B. Chapman and John M. Kirkwood and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

C. Morris

19 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Morris United Kingdom 8 275 248 125 93 72 19 494
Justine Yu United States 11 285 1.0× 176 0.7× 118 0.9× 90 1.0× 67 0.9× 15 579
Maria Hersom Denmark 9 267 1.0× 326 1.3× 179 1.4× 71 0.8× 55 0.8× 10 760
Sarah Short United States 6 271 1.0× 170 0.7× 63 0.5× 115 1.2× 43 0.6× 10 481
M. Lafitte France 14 401 1.5× 146 0.6× 65 0.5× 146 1.6× 49 0.7× 28 723
Capella Weems United States 9 564 2.1× 246 1.0× 76 0.6× 118 1.3× 41 0.6× 9 748
Eftychia Oikonomou Greece 13 330 1.2× 273 1.1× 69 0.6× 135 1.5× 47 0.7× 16 597
Tilahun Jiffar United States 13 371 1.3× 213 0.9× 47 0.4× 111 1.2× 70 1.0× 14 636
Kathryn M. Kinross Australia 9 409 1.5× 158 0.6× 77 0.6× 88 0.9× 50 0.7× 16 632
Oriol Arqués Spain 9 578 2.1× 237 1.0× 106 0.8× 126 1.4× 40 0.6× 11 762
Mahn Joon Ha South Korea 7 341 1.2× 160 0.6× 136 1.1× 127 1.4× 84 1.2× 11 533

Countries citing papers authored by C. Morris

Since Specialization
Citations

This map shows the geographic impact of C. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Morris more than expected).

Fields of papers citing papers by C. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Morris. The network helps show where C. Morris may publish in the future.

Co-authorship network of co-authors of C. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of C. Morris. A scholar is included among the top collaborators of C. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Morris. C. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Morris, C., Paul G. Waddell, Adrian C. Whitwood, et al.. (2025). Stereoselective synthesis of atropisomeric amides enabled by intramolecular acyl transfer. Chemical Science. 16(9). 3938–3945. 3 indexed citations
2.
Morris, C., et al.. (2022). Can the type of subjective response to first opioid exposure predict the risk of opioid use disorder? A scoping review. Brain Research Bulletin. 188. 67–76. 2 indexed citations
3.
Vasseur, Damien, Mihaela Aldea, Charles Naltet, et al.. (2021). 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy. Annals of Oncology. 32. S991–S991. 1 indexed citations
4.
Xi, Liqiang, Constance M. Cultraro, Fengcai Wei, et al.. (2019). P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 14(10). S366–S366. 1 indexed citations
5.
6.
Mezquita, Laura, David Planchard, Mihaela Aldea, et al.. (2019). Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. Annals of Oncology. 30. ix122–ix123. 5 indexed citations
7.
Mezquita, Laura, Aurélie Swalduz, Mihaela Aldea, et al.. (2019). Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC). Annals of Oncology. 30. v641–v641. 3 indexed citations
8.
9.
Mezquita, Laura, Cécile Jovelet, Maud Ngo‐Camus, et al.. (2017). MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(11). S1843–S1843. 1 indexed citations
10.
Board, Ruth, Gillian Ellison, Maria Orr, et al.. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. British Journal of Cancer. 101(10). 1724–1730. 78 indexed citations
11.
12.
Banerji, Udai, D. Ross Camidge, Kathryn H. Brown, et al.. (2008). The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 3535–3535. 6 indexed citations
13.
Dummer, Reinhard, Caroline Robert, Paul B. Chapman, et al.. (2008). AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. Journal of Clinical Oncology. 26(15_suppl). 9033–9033. 103 indexed citations
14.
Stone, A, et al.. (2007). Myths in the assessment of progression: How frequently should we assess patients in clinical trials?. Journal of Clinical Oncology. 25(18_suppl). 6521–6521. 1 indexed citations
15.
Schellens, Jan H.M., David S. Boss, Anthe S. Zandvliet, et al.. (2006). Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. Journal of Clinical Oncology. 24(18_suppl). 3008–3008. 47 indexed citations
16.
Warren, Katherine, Gerald W. Chodak, W. A. See, et al.. (2006). Are Bone Scans Necessary in Men With Low Prostate Specific Antigen Levels Following Localized Therapy?. The Journal of Urology. 176(1). 70–74. 9 indexed citations
17.
Adjei, Alex A., Robert Cohen, Wilbur A. Franklin, et al.. (2006). 26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies. European Journal of Cancer Supplements. 4(12). 12–12. 6 indexed citations
18.
Morris, C.. (2001). Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence. The American Journal of Gastroenterology. 96(4). 990–996. 76 indexed citations
19.
Morris, C., Gordon Rustin, Stephen R. Wedge, et al.. (1998). O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. British Journal of Cancer. 78(9). 1199–1202. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justine Yu Breakdown of academic impact, for papers by Maria Hersom Breakdown of academic impact, for papers by Sarah Short Breakdown of academic impact, for papers by M. Lafitte Breakdown of academic impact, for papers by Capella Weems Breakdown of academic impact, for papers by Eftychia Oikonomou Breakdown of academic impact, for papers by Tilahun Jiffar Breakdown of academic impact, for papers by Kathryn M. Kinross Breakdown of academic impact, for papers by Oriol Arqués Breakdown of academic impact, for papers by Mahn Joon Ha
Rankless by CCL
2026